Type of Spiritual Experience
A description of the experience
Depot medroxyprogesterone acetate (DMPA) is a long-acting reversible hormonal contraceptive birth control drug that is injected every three months. It is a progestin-only contraceptive. It is marketed under the brand name Depo-Provera.
It is an aqueous suspension for depot injection of the pregnane 17α-hydroxyprogesterone-derivative progestin medroxyprogesterone acetate.
Depo-Provera is the brand name for a 150 mg aqueous injection of DMPA depot medroxyprogesterone acetate. It is applied in the form of an intramuscular injection. The medicine must be injected into the thigh or buttocks or deltoid four times a year (every 11 to 13 weeks) and provides pregnancy protection starting a week after the first injection. It was approved in the United States by the FDA for contraceptive use on 29 October 1992, and for management of endometriosis-related pain on 25 March 2005.Depo-subQ Provera 104, is a variation of the original Depo Shot that is instead a 104 mg subcutaneous injection. It contains 69 percent of progestin found in the original Depo-Provera shot. This can be injected using a smaller injection needle inserting the hormone just below the skin, instead of into the muscle, in either the abdomen or thigh. This subcutaneous injection reduces the side effects of the progestin while still maintaining all the same benefits of the original Depo shot.
On Jan, 20, 2017 11,576 people reported to have side effects when taking Depo-provera. Among them, 35 people (0.3%) have Hallucination
Time on Depo-provera when people have Hallucinations :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years|
Age of people who have Hallucinations when taking Depo-provera :
While it has long been known that Depo-Provera causes bone loss, it has recently been discovered that the osteoporotic effects of the injection grow worse the longer Depo-Provera is administered, may remain long after the injections are stopped, and may be irreversible. For these reasons, on November 17, 2004 the United States Food and Drug Administration and Pfizer agreed to put a black box warning on Depo-Provera's label.
It is unclear whether the bone density loss associated with Depo-Provera use is reversible, and if so, how completely.
Pfizer and the FDA recommend that Depo-Provera not be used for longer than 2 years, unless there is no viable alternative method of contraception, due to concerns over bone loss.
In the largest clinical trial of Depo-Provera, the most frequently reported adverse reactions (which may or may not be related to the use of Depo-Provera) were: menstrual irregularities (bleeding or amenorrhea or both), abdominal pain or discomfort, weight changes, headache, asthenia (weakness or fatigue), hair loss and nervousness. Other, less frequently reported adverse reactions are listed in the patient and physician label information for Depo-Provera.